Revenue Dynamics YoY (Last Twelve Months): Traws Pharma, Inc. (TRAW)

Graphic logo of Traws Pharma Inc (TRAW)

Traws Pharma, Inc. (TRAW) is a promising developer of oral treatments for COVID-19 and influenza. The relative change in rolling year revenue compared to the same period last year demonstrates revenue dynamics, where -99.80 represents the latest level. Asset security is guaranteed by the absence of sanctions and a reliance on US science. The management team focuses on creating convenient therapies, ensuring the technological superiority of its pipeline.

TRAW Traws Pharma, Inc.: Revenue Growth YoY (Last 12 Months) in the range 11/23/2025 - 11/18/2026

Traws Pharma, Inc. - analytical breakdowns and key metrics (TRAW)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Analysis of all company metrics:trawspharma.com, TRAW
Signature product of Traws Therapeutics

Investors are seeking fundamental benchmarks to assess business resilience within financial statements. This metric measures the percentage change in revenue over a rolling year, excluding seasonal distortions. Analyzing the 12-month trailing sales dynamics year-over-year allows for the distinction between a temporary downturn and a systemic crisis. For Traws Pharma, Inc. (TRAW), this serves as an indicator of the commercialization of antiviral drugs. Growth in this metric confirms the effectiveness of the strategy to create affordable medications for influenza and COVID-19.